We have located links that may give you full text access.
Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research 2017 October 3
BACKGROUND Breast cancer is among the deadliest cancers across the world and is responsible for countless deaths. There is an urgent need for co-delivery systems which can simultaneously transport both drug and gene into a single cancer cell with low toxicity and high anti-angiogenesis efficiency. MATERIAL AND METHODS In the present study, well-formed amine-functionalized hydroxyapatite nanoparticles based on combined angiogenesis therapy for breast cancer were successfully constructed for the simultaneous delivery of p53 and candesartan (CD) (p53/CD/NHAP). RESULTS In vitro and in vivo experiments revealed that p53/CD/NHAP can effectively transfer the p53 gene and deliver the loaded CD to achieve preferable anti-breast cancer effect both at the cellular level and in tumor-bearing mice. This may possibly be due to the combined anti-angiogenic mechanisms of p53 and CD via different pathways. CONCLUSIONS p53/CD/NHAP might be a candidate carrier for efficient anti-angiogenesis therapy of breast cancer.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app